Bi-specific monoclonal antibody (specific for both CD3 and CD11b) therapeutic drug
View Patent ↗The present invention relates to the treatment of immune system abnormalities that can be found in lethal human cancers and also in the progressive Human Immunodeficiency Virus Type 1 (HIV-1) infections and provides medicaments to correct abnormalities in a subject with cancer or HIV-1-infected subjects, in order to allow the immune system to fight the cancer or HIV-1 infections. The present invention also discloses multivalent polypeptides which specifically bind to and enable destruction and/or inactivation of immune cells that have CD11b and CD3 on their surface, therefore dissipating the deleterious effects of the CD11b + T cells.
1. An isolated multivalent polypeptide which specifically binds to CD3 and CD11b surface markers, wherein the CD3 marker and the CD11b marker are simultaneously expressed on the surface of a regulatory T cell from a subject having B-cell chronic lymphocytic leukemia (B-CLL).
2. The multivalent polypeptide of claim 1 , wherein the polypeptide comprises an antibody or fragments thereof.
3. The multivalent polypeptide of claim 2 , wherein the antibody is human, humanized, or chimeric.
4. The multivalent polypeptide of claim 3 , wherein the antibody is a bispecific antibody.
5. The multivalent polypeptide of claim 1 , wherein the multivalent polypeptide is conjugated to a cytotoxic agent.
6. The multivalent polypeptide of claim 5 , wherein the cytotoxic agent is a radionuclide.
7. The multivalent polypeptide of claim 6 , wherein the radionuclide is selected from the group consisting of p 32 , p 33 , Sc 47 , Cu 64 , Cu 67 , As 77 , Y 90 , PH 105 , Pd 109 , Ag 111 , I 125 , Pr 143 , Sm 153 , Tb 161 , Lu 177 , Re 186 , Re 188 , Re 189 , Ir 194 , Au 199 , Pb 212 , and Bi 213 .
8. A kit comprising the multivalent polypeptide of claim 1 , a label, and instructions for using the multivalent polypeptide.
9. The kit of claim 8 , wherein the instructions provide a method of prognosis of the effectiveness of the multivalent polypeptide in the subject comprising determining a subpopulation of regulatory T cells simultaneously expressing CD3 and CD11b cell surface markers.